Jefferies Starts Valeant Pharmaceuticals (VRX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall St set for strongest quarter in years as risk appetite holds despite US-Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
TD Securities Upgrades Valeant Pharmaceuticals (VRX) to Buy
April 23, 2014 7:23 AM EDTTD Securities upgraded Valeant Pharmaceuticals (NYSE: VRX) from Hold to Buy with a price target of $160.00 (from $145.00). The change follows news it is teaming with Bill Ackman to acquire Allergan.
Analyst Lennox Gibbs said, "The proposed transaction could substantially... More
